indication advanced gastric cancer, is an oral combination of Tegafur (a prodrug of 5FU) and two inhibitor enzymes – Gimeracil and Oteracil.

Gimeracil inhibits the metabolism of 5FU by reversibly and selectively inhibiting dihydropyrimidine dehydrogenase (DPD), maintaining increased exposure to 5FU with low tegafur doses.

Oteracil inhibits orotate phosphoribosyltransferase and reduces gastrointestinal toxicities without compromising the desired antitumour effects of Tegafur.


To give you a better experience on our websites, we place cookies on your computer, phone or tablet.
By continuing to use this site we will assume that you are happy with this.

I understand